Clinical Trial Detail

NCT ID NCT02733042
Title A Study to Determine Dose, Safety, and Efficacy of Durvalumab as Monotherapy and in Combination Therapy in Subjects With Lymphoma or Chronic Lymphocytic Leukemia (FUSION NHL 001)
Recruitment Active, not recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Celgene Corporation
Indications

chronic lymphocytic leukemia

B-cell lymphoma

Therapies

Rituximab

Durvalumab + Lenalidomide + Rituximab

Bendamustine + Durvalumab + Rituximab

Durvalumab + Ibrutinib

Durvalumab

Age Groups: adult

No variant requirements are available.